問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
沈佳儀
下載
2022-11-30 - 2028-11-28
Condition/Disease
Test Drug
Participate Sites9Sites
Recruiting9Sites
2022-03-01 - 2026-12-31
2024-09-01 - 2029-02-05
Participate Sites8Sites
Not yet recruiting4Sites
Recruiting3Sites
2025-10-01 - 2035-01-20
Participate Sites6Sites
Recruiting6Sites
2025-10-01 - 2028-12-31
2025-09-01 - 2028-09-30
Participate Sites5Sites
Recruiting5Sites
2024-11-29 - 2027-09-30
2024-03-28 - 2026-08-28
2023-05-01 - 2025-12-31
Participate Sites1Sites
Recruiting1Sites
2020-03-01 - 2022-12-30
Advanced/Metastatic solid tumors
V941 (mRNA-5671)/ Pembrolizumab
Participate Sites3Sites
全部
